ACOART BTK RENEW：A Post Market Clinical Study

Who May Qualify: - 1\. Age ≥18 years old and ≤75 years old - 2\. Rutherford clinical category classification：3,4 or 5 - 3\. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in below-the-knee arteries which distal bloodflow is patent. - 4\. Reference vessel diameter is between 2 mm and 4 mm - 5\. Subject has provided written willing to sign a consent form prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments. Who Should NOT Join This Trial: - 1\. Plasma creatinine clearance rate \<30 mL/min - 2\. Acute vessel occlusion or acute thrombosis in target lesion - 3\. Planned amputation on the target limb - 4\. Subjects confined to bed that are completely non-ambulatory. - 5\. Thrombolytic therapy or surgical procedure on the target limb within 6 weeks prior to enrollment. - 6\. Life expectancy \< 5 year. - 7\. Cumulative length of 100% occluded target lesion(s)\>150 mm - 8\. In-stent restenosis within the target lesion, or the distance between the target lesions and the stent was less than 20 mm - 9\. History of stroke within 90 days prior to enrollment - 10\. Known allergy to contrast agents, antiplatelet, anticoagulant, or thrombolytic therapy - 11\. Uncorrectable bleeding diathesis - 12\. The lesion of the inflow pathway cannot be identified due to the complete occlusion of the P3 segment of the popliteal artery - 13\. Pregnant or breastfeeding female subjects - 14\. Ability to cross a guidewire through target lesion - 15\. Patients who have participated in clinical trials of other medical devices or drugs during the same period Always talk to your doctor about whether this trial is right for you.